Maribavir is an orally available, antiviral agent which inhibits the pUL97 kinase of cytomegalovirus (CMV) and is used to treat refractory forms of post-transplant CMV infection. Maribavir has been associated with low rates of mild-to-moderate serum aminotransferase elevations during therapy but has not been linked to cases of clinically apparent acute liver injury. Its therapeutic use is listed as anti-infectives and antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Benzimidavir, livtencity, Camvia and BW-1263W94. Its PubChem CID is 471161.
Maribavir
| CAS No | 176161-24-3 |
|---|---|
| Molecular Formula | C15H19Cl2N3O4 |
| Molecular Weight | 376.20 g/mol |
| Synonyms | (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Maribavir is an orally available, antiviral agent which inhibits the pUL97 kinase of cytomegalovirus (CMV) and is used to treat refractory forms of post-transplant CMV infection.
The listed CAS number is 176161-24-3.
The listed molecular formula is C15H19Cl2N3O4.
The listed molecular weight is 376.20 g/mol.
(2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol.
The source lists Benzimidavir, livtencity, Camvia and BW-1263W94.